LI Wen-Juan,CHEN Hui-Jin. Research progress in ischemia-induced abnormal glutamatergic signaling in immature cerebral white matter[J]. 中国当代儿科杂志, 2011, 13(3): 268-272.
LI Wen-Juan,CHEN Hui-Jin. Research progress in ischemia-induced abnormal glutamatergic signaling in immature cerebral white matter[J]. CJCP, 2011, 13(3): 268-272.
［1］Khwaja O, Volpe JJ. Pathogenesis of cerebral white injury of prematurity［J］. Arch Dis Child Fetal Neonate Ed, 2008, 93(2): 153-161.
［2］Bakiri Y, Burzomato V, Frugier G, Hamilton NB, Karadottir R, Attwell D. Glutamatergic signaling in the brain's white matter［J］. Neuroscience, 2009,158(1):266-274.
［3］Káradóttir R, Attwell D. Neurotransmitter receptors in the life and death of oligodendrocytes［J］.Neuroscience, 2007, 145(4): 1426-1438.
［4］Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury［J］. J Neurosci, 2001, 21(4): 1302-1312.
［5］Talos DM, Follett PL, Folkerth RD, Fishman RE, Trachtenberg FL, Volpe JJ, et al. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex［J］. J Comp Neurol, 2006, 497(1): 61-77.
［6］Verkhratsky A, Kirchhoff F. NMDA receptors in glia［J］. Neuroscientist, 2007, 13(1):28-37.
［7］Arranz AM, Hussein A, Alix JJ, Pérez-Cerdá F, Allcock N, Matute C, et al. Functional glutamate transport in rodent optic nerve axons and glia［J］. glia, 2008, 56(12): 1353-1367.
［8］Matute C, Alberdi E, Domercq M, Sánchez-Gómez MV, Pérez-Samartín A, Rodríguez-Antigüedad A, et al. Excitotoxic damage to white matter［J］. J Anat, 2007, 210(6):693-702.
［9］Arranz AM , Gottlieb M, Pérez-Cerdá F, Matute C. Increased expression of glutamate transporters in subcortical white matter after transient focal cerebral ischemia［J］. Neurobiol Dis, 2010, 37(1): 156-165.
［10］Stys PK, Lipton SA. White matter NMDA receptors: an unexpected new therapeutic target?［J］. Trends Pharmacol Sci, 2007, 28(11):561566.
［11］Sasaki YF, Rothe T, Premkumar LS, Das S, Cui J, Talantova MV, et al. Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons［J］. J Neurophysiol, 2002, 87(4):20522063.
［12］Káradóttir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia［J］. Nature, 2005, 438(7071): 1162-1166.
［13］Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate ［J ］. J Neurosci, 2004, 24(18): 4412-4420.
［14］Wang C, Pralong WF, Schulz MF, Rougon G, Aubry JM, Pagliusi S, et al. Functional N-methyl-D-aspartate receptors in O-2A glial precursor cells: a critical role in regulating polysialic acid-neural cell adhesion molecule expression and cell migration［J］. J Cell Biol, 1996,135(6 Pt 1): 1565-1581.
［15］Wilke S, Allcock N, Thomas R, Fern R. Mechanism of acute ischemic injury of oligodendroglia in early myelinating white matter: The importance of astrocyte injury and glutamate release［J］. J Neuropathol Exp Neurol, 2004, 63(8):872-881.
［16］Matute C, Domercq M, S-nchez-Gómez MV. Glutamate-mediated glia injury: mechanisms and clinical importance［J］. Glia, 2006, 53(2): 212-224.
［17］Underhill SM, Goldberg MP. Hypoxic injury of isolated axons is independent of ionotropic glutamate receptors［J］. Neurobiol Dis,2007, 25(2): 284-290.
［18］Rosenberg PA, Dai W, Gan XD, Ali S, Fu J, Back SA, et al. Mature myelin basic protein-expressing oligodendrocytes are insensitive to kainate toxicity［J］. J Neurosci Res, 2003, 71(2):237-245.
［19］Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia［J］. Nature, 2006, 439(7079): 988-992.
［20］Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology［J］. Curr Opin Pharmacol, 2007, 7(1):39-47.
［21］Parsons CG, Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker［J］. Methods Mol Biol, 2007, 403:15-36.
［22］Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials［J］. Drug Saf, 2008,31(7):577-585.
［23］Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, et al. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients［J］. Alzheimer Dis Assoc Disord, 2008, 22(2):125-130.
［24］Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-diseasemodel transgenic mice shown as by micromagnetic resonance imaging［J］. J Neurosci Res, 2008, 86(12):2784-2791.
［26］Chen H, Liu Z, Zhou Z, Jiang M, Qian L, Wu S. The regulatory effect of memantine on expression and synthesis of heat shock protein 70 gene in neonatal rat models with cerenbral hypoxic ischemia［J］. Chin Med J (Engl), 2003, 116(4): 558-564.
［30］Manning SM, Talos DM, Zhou C, Sepip DB, Park HK, Park CJ, et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia［J］. J neurosci, 2008, 28(26):6670-6678.
［31］Ganel R, Ho T, Maragakis NJ, Jackson M, Steiner JP, Rothstein JD. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection［J］. Neurobiol Dis, 2006, 21(3): 556-567.
［32］Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression［J］. Nature, 2005, 433(7021): 73-77.
［33］Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes［J］. J Biol Chem, 2008, 283(19): 13116-13123.
［34］Romera C, Hurtado O, Botella SH, Lizasoain I, Cárdenas A, Fernández-Tomé P, et al. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway［J］. J Neurosci, 2004, 24(6):1350-1357.
